



Biotech Daily

Monday August 11, 2025

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: CURVEBEAM UP 13%; SYNTARA DOWN 53%**
- * **SYNTARA: FDA WANTS 2nd PHASE II SNT-5505 TRIAL BEFORE PHASE III**
- * **MICROBA SHARE PLAN RAISES \$2m; TOTAL \$14.5m**
- * **ANTEOTECH RECEIVES \$2.6m FEDERAL R&D TAX INCENTIVE**
- * **ISLAND \$350k FROM MWP OPTIONS EXERCISE**
- * **NOXOPHARM DOSES 2nd PHASE I SOF-SKN COHORT, 'NO ISSUES'**
- * **CURVEBEAM TO RELEASE 69m ASX ESCROW SHARES**
- * **FIL (FIDELITY) TAKES 8.5% OF RHYTHM**
- * **LTR APPOINTS DR AMY PEARLMAN SCIENTIFIC ADVISOR**

MARKET REPORT

The Australian stock market was up 0.43 percent on Monday August 11, 2025, with the ASX200 up 37.7 points to 8,844.8 points.

Thirteen of the Biotech Daily Top 40 companies were up, 21 fell and six traded unchanged.

Curvebeam was the best, up 1.5 cents or 13.0 percent to 13 cents, with 819,344 shares traded. 4D Medical climbed 12.9 percent; Starpharma was up 10 percent; Actinogen improved 8.8 percent; Prescient was up 7.3 percent; Atomo climbed 5.3 percent; Genetic Signatures was up 3.2 percent; Emvision, Polynovo, Resonance and SDI rose two percent or more; CSL, Nanosonics and Resmed were up more than one percent; with Cochlear and Orthocell up by less than one percent.

Syntara led the falls (see below), down three cents or 52.6 percent to 2.7 cents, with 119.8 million shares traded. Universal Biosensors lost 8.7 percent; Amplia fell 7.3 percent; Avita and Cyclopharm shed more than six percent; Dimerix fell 5.8 percent; Compumedics and Telix lost more than four percent; Immutep, Nova Eye and Optiscan were down more than three percent; EBR and Impedimed shed more than two percent; Clarity, Clinuvel, Medadvisor, Micro-X and Pro Medicus were down more than one percent; with Aroa, Medical Developments, Mesoblast and Neuren down by less than one percent.

SYNTARA

Syntara says it has US Food and Drug Administration guidance to conduct a phase II trial of amsulostat, or SNT-5505, for myelofibrosis with a control arm prior to a phase III trial. Last year, Syntara said it dosed all 15 patients in a phase II trial of SNT-5505 with ruxolitinib for the bone marrow cancer myelofibrosis (BD: Jul 31, 2024).

Earlier this year, the company said 24-week data from the phase II trial showed that SNT-5505 led to eight of 11 evaluable patients with a 50 percent or more improvement of myelofibrosis symptoms (BD: Jun 13, 2025).

In July, Syntara said that SNT-5505, formerly PXS-5505 had been renamed by the World Health Organisation as amsulostat.

Today, the company said during a type C meeting the FDA had reviewed a comprehensive data package that included interim data from its ongoing open-label trial of amsulostat with ruxolitinib, as well as a proposal for a registrational study.

Syntara said the FDA had “provided guidance that a phase II trial with a control arm be undertaken to acquire additional safety and efficacy data, focusing on improvements in symptoms and spleen volume reductions in order to optimize the design and efficiency of a subsequent pivotal phase III trial”.

Syntara managing-director Gary Phillips said the company would “use the FDA guidance to refine our clinical development plan for amsulostat and continue discussions with partners based on the FDA recommended path forward”.

“Syntara is in a strong position given the depth and quality of our pipeline and a cash runway that will take us into 2027,” Mr Phillips said. “We look forward to sharing results from our ongoing clinical trials over the coming months.”

Syntara fell three cents or 52.6 percent to 2.7 cents with 119.8 million shares traded.

MICROBA LIFE SCIENCES

Microba says it has raised \$2.0 million at nine cents a share in an underwritten share purchase plan, taking the total raised with the placement to \$14.5 million.

In June, Microba said it had raised \$12.5 million at 9.0 cents a share in a placement, a 25.9 percent discount to the five-day volume weighted average price, with a \$2 million, fully-underwritten share purchase plan to follow (BD: Jun 23, 2025).

Today, the company said the share purchase plan was oversubscribed, with valid applications totalling \$2,196,000, and that the amount was scaled back to \$2,000,000.

Microba said investors would receive one option for every two shares issued, exercisable at 14 cents each within two years.

The company said the share purchase plan securities as well as the second tranche of the placement had been approved by shareholders last Friday, August 8, 2025, and would be issued on Wednesday, August 13, 2025.

Microba said the funds raised would be used to increase clinical adoption of its microbiome testing products.

Microba fell 0.1 cents or 1.1 percent to nine cents.

ANTEOTECH

Anteotech says it has received \$2.59 million from the Australian Taxation Office under the Federal Government’s Research and Development Tax Incentive program.

Anteotech said the incentive related to expenditure for its advanced battery technologies and life science businesses during the year to June 30, 2025.

Anteotech was up 0.1 cents or 4.35 percent to 2.4 cents with 29.3 million shares traded.

ISLAND PHARMACEUTICALS

Island says it has raised \$350,000 from Hong Kong-based substantial shareholder MWP Partners exercising 5,000,000 options at seven cents each.

Island said the options increased MWP Partners' shareholding and marked "a considerable vote of confidence in the company's dual asset development strategy". The company said the funds provide "with further financial flexibility to advance its dual asset development strategy", including ISLA-101 for dengue fever and Galidesivir for Marburg virus.

In June, Island said its 14-patient, phase IIa/b trial showed ISLA-101 led to a "clear reduction in [dengue] virus level ... [and] a material reduction in viral load and symptoms" (BD: Jun 12, 2025).

Last month, the company said it completed its up-to \$US2.5 million (\$A3.8 million) acquisition of the Durham, North Carolina-based Biocryst Pharmaceuticals' galidesivir anti-viral program, and intended to submit documentation of the program to the US regulatory by October for a potential animal study in Marburg virus (BD: Jul 31, 2025). Island managing-director Dr David Foster said the "support from a second substantial shareholder provides a significant vote of confidence in the company and its clinical development strategy for both ISLA-101 and Galidesivir".

Last month, co-founder and former director Dr William Garner exercised options raising \$779,944 (BD: Jul 17, 2025).

Island fell half a cent or 2.4 percent to 20.5 cents.

NOXOPHARM

Noxopharm says it has dosed the second cohort in its 16-patient, phase I, 'Heracles' trial of SOF-SKN for auto-immune disease, with "no clinically relevant issues found".

Earlier this year, Noxopharm said it had ethics approval for its first in-human, 'Heracles' phase I trial of SOF-SKN for autoimmune disease (BD: May 29, 2025).

Last month, the company said it dosed the first of 16 volunteers with its Sofra-based SOF-SKN in its phase I 'Heracles' trial for autoimmune diseases (BD: Jul 16, 2025).

At that time, Noxopharm said the study would "evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations" but did not disclose the dose concentrations.

Today, the company said the second dose level was safe and tolerable and that the trial would "proceed to the third cohort of participants, who will receive a higher dose".

Noxopharm was up half a cent or 4.55 percent to 11.5 cents with 1.9 million shares traded.

CURVEBEAM A.I.

Curvebeam says it will release 69,230,721 shares from ASX escrow and 17,766,774 shares from voluntary escrow on August 22, 2025.

According to its most recent notice, Curvebeam had 321,042,420 shares on issue, meaning that following the release from ASX escrow it would have 390,273,141 shares available for trading.

The company said there would be "no securities remaining in escrow following the release of the above securities on August 22, 2025".

Curvebeam said its directors, their related parties, management and senior leaders in the business held 89 percent of the shares being released from escrow.

Curvebeam was up 1.5 cents or 13.0 percent to 13 cents.

RHYTHM BIOSCIENCES

FIL Investment Management Ltd says it has increased its substantial shareholding in Rhythm from 20,645,216 shares (7.11%) to 24,811,804 shares (8.53%).

The Sydney and Hong Kong-based FIL (Fidelity) said that it bought shares between July 2 and August 6, 2025 at prices ranging from 5.12 cents a share to 15.14 cents a share. Rhythm was unchanged at 10.5 cents with 4.5 million shares traded.

LTR PHARMA

LTR says it has appointed urologist Dr Amy Pearlman to its scientific advisory board.

LTR said Dr Pearlman was co-founder of Prime Institute, a private medical practice focused on optimizing cardio-metabolic, hormonal and sexual health in men and women and a former director of the men's health at the University of Iowa.

The company said Dr Pearlman would "provide strategic clinical insight, medical engagement, and market access strategies for Spontan and Roxus, the company's innovative nasal spray treatments for erectile dysfunction".

LTR said Dr Pearlman's appointment enhanced its "clinical expertise as it prepares for expansion into the US market".

The company said Dr Pearlman's "deep understanding of the American healthcare landscape, established relationships with key opinion leaders, and a proven record in advancing innovative treatments will be instrumental in positioning Spontan and Roxus for success in North America".

LTR was up one cent or 3.1 percent to 33.5 cents.